Videos

Dosing and Sequencing Bispecifics and CAR T-Cell Therapies in R/R MM

Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.

Krina K. Patel, MD;Sairah Ahmed, MD;Melody R. Becnel, MD ;Tejo N. Musunuru, MD

Unmet Needs and Future Perspectives on Colorectal Cancer

Key opinion leaders share comprehensive insight on optimal dosing and sequencing strategies in patients with relapsed/refractory multiple myeloma.

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

RRMM: Access to Bispecifics and CAR T-Cell Therapy in Satellite Campuses

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in colorectal cancer.

Krina K. Patel, MD;Sairah Ahmed, MD;Melody R. Becnel, MD ;Tejo N. Musunuru, MD

‘Future Is Bright’ With Bispecifics for Relapsed/Refractory Myeloma

A brief conversation on the introduction and use of bispecifics and CAR T-cell therapies in satellite campuses for patients with relapsed/refractory multiple myeloma.

$An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.$

Bhagirathbhai Dholaria, MBBS

June 3rd 2023

An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.

Maintenance Therapy Regimens for Patients With Transplant-Eligible MM

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

June 2nd 2023

An expert panel discusses maintenance therapy for patients with MM and offers insights on how induction therapy impacts treatment options.

Determining Transplant Eligibility in Newly Diagnosed MM

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

June 2nd 2023

Experts on multiple myeloma (MM) discuss factors that determine transplant eligibility for patients who are newly diagnosed.

Evaluating Immune Checkpoint Inhibitors for Advanced/Recurrent Endometrial Cancer by MRR Status

Robert L. Coleman, MD, FACOG, FACS;Ramez Eskander, MD;Sharyn Lewin, MD, FACS

Patient Education on Treatment With Immune Checkpoint Inhibitors for Advanced/Recurrent Endometrial Cancer

Drs Eskander and Lewin discuss the sequencing immune checkpoint inhibitors for women with recurrent endometrial cancer.

Robert L. Coleman, MD, FACOG, FACS;Ramez Eskander, MD;Sharyn Lewin, MD, FACS

Approval of Olaparib Combo Impacts SOC in BRCA-Mutant Metastatic CRPC

Sharyn Lewin, MD, FACS, shares how she discusses side effects with patients receiving immune checkpoint inhibitors for advanced/recurrent endometrial cancer.

Andrew J. Armstrong, MD, MSc

First-Line Treatment Options for Patients With Transplant-Ineligible NDMM

Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

Treatment Considerations for Patients with High-Risk NDMM

Ashley Rosko, MD, presents the case of a 79-year-old female with transplant-ineligible newly-diagnosed multiple myeloma.

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment

Barry Hammer, PA-C, defines high-risk multiple myeloma and explains the treatment adjustments needed for newly-diagnosed patients.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)

Dr Cindy Varga discusses recent data on the FDA-approved agent teclistamab, a bispecific antibody for patients with relapsed/refractory multiple myeloma.

$Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)$

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM

Binod Dhakal, MD, MS, discusses the management of relapsed multiple myeloma and the various treatment options available.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Bacterial Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies

Maria-Victoria Mateos, MD, PhD, reviews how she manages the side effects of teclistamab, including cytokine release syndrome, in patients with relapsed/refractory multiple myeloma.

Ajai Chari, MD;Kiah Purcell, AGPCNP-B;Annel Urena, RN, BSN;Robert Mancini, PharmD, BCOP

Case 3: A 49-Year-Old with R/R MM Treated with Bispecifics and Develops Adenoviral Infection

Dr Robert Mancini details the bacterial infections usually seen in multiple myeloma patients treated with anti-BCMA bispecific antibodies.

Saad Z. Usmani, MD, MBA, FACP;Carlyn Tan, MD;Michael Scordo, MD;Anna Howard, RN

Data on Infections and Severe Hypogammaglobulinemia in MM Patients Treated with Anti-BCMA Bispecific Antibodies

An expert panel discusses the case of a 49-year-old with relapsed/refractory multiple myeloma treated with a BCMA bispecific antibody who develops adenoviral infection.

Ajai Chari, MD;Kiah Purcell, AGPCNP-B;Annel Urena, RN, BSN;Robert Mancini, PharmD, BCOP

Mechanism of Action of Teclistamab in R/R MM and Data Updates

Dr Ajai Chari reviews data from a study looking at the rates of infection in patients with multiple myeloma treated with BCMA-targeting bispecific antibodies, including severe hypogammaglobulinemia.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Clinical Pearls on CRS and ICANS Management in Multiple Myeloma

Melissa Alsina, MD, explains the mechanism of action, data updates and dosing schedule of the BCMA-targeting bispecific antibody teclistamab.

Ajai Chari, MD;Annel Urena, RN;Kiah Purcell, NP;Robert Mancini, PharmD, BCOP

Managing Toxicities in Patients With MM Treated with ASCT or Novel Therapies

Moderator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.

Saad Z. Usmani, MD, MBA, FACP;Carlyn Tan, MD;Michael Scordo, MD;Anna Howard, RN

The Importance of Access to Care for Multiple Myeloma in Community Settings

Michael Scordo, MD, gives an overview of a study on dysgeusia seen in patients with multiple myeloma following autologous stem cell transplant or treatment with novel agents.

For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.

Expanding the Treatment Armamentarium in RRMM with Novel Therapies

May 30th 2023

For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.

Krina K. Patel, MD;Sairah Ahmed, MD;Melody R. Becnel, MD ;Tejo N. Musunuru, MD

Trials Focused on ctDNA in Colorectal Cancer

Switching focus to the relapsed/refractory setting, panelists reflect on the treatment armamentarium available to patients with multiple myeloma at early relapse.

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma

An expert panel discusses clinical trials focused on circulating tumor DNA in guiding treatment selection in colorectal cancer.

Krina K. Patel, MD;Sairah Ahmed, MD;Melody R. Becnel, MD ;Tejo N. Musunuru, MD

SUNLIGHT and FRESCO-2 Trials in Refractory Colorectal Cancer

Key opinion leaders in multiple myeloma consider duration of therapy and the possibility of treatment discontinuation for newly diagnosed patients.

Arvind Dasari, MD, MS, an expert on colorectal cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

CARE Clinic Uses Multidisciplinary Approach For Geriatric Multiple Myeloma

An overview of the SUNLIGHT and FRESCO-2 studies in the refractory colorectal cancer space.

Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.

Using ‘Intensity’ to Gain ‘Deep Control’ in Myeloma at Ohio State

May 28th 2023

Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.

At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.

BiTE Therapy May Impact Standard of Care in Multiple Myeloma, Expert Says

May 27th 2023

At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.

Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.